Skip to main content
PegBio Co., Ltd. logo

PegBio Co., Ltd. — Investor Relations & Filings

Ticker · 2565 ISIN · CNE100006T44 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 2,132 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2565

About PegBio Co., Ltd.

http://www.pegbio.com

PegBio Co., Ltd. is a biotechnology company specializing in the in-house discovery and development of innovative therapies for chronic diseases, primarily focusing on the endocrine and metabolic fields. The company leverages its proprietary HECTORTM technology system to design and screen novel molecular entities, including peptide, protein, and small-molecule drugs, targeting unmet clinical needs. PegBio's robust pipeline addresses major chronic conditions such as Type 2 Diabetes (T2DM), obesity, and metabolic dysfunction-associated steatohepatitis (MASH). Key pipeline assets include long-acting GLP-1 receptor agonists, such as Vepinatide, developed for T2DM treatment and weight management. The company emphasizes creating complementary, multi-benefit product pipelines characterized by new targets, new sites, and new mechanisms of action.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT PEGBIO RECEIVES FIRST ROYALTY PAYMENT OF HK$61 MILLION FROM TENRY PHARMACEUTICAL FOR VISEPEGENATIDE COMMERCIALIZATION COLLABORATION
Regulatory Filings Classification · 54% confidence The document is a voluntary corporate announcement on the Hong Kong Exchange about receiving a first royalty payment under a commercialization collaboration. It provides a business update rather than presenting financial statements, management discussion, a report publication, or any specific capital-raising activity. It does not fit specialized categories (e.g., earnings release, financing, share issue, M&A, regulatory stress test). As a miscellaneous announcement filed with the exchange, it falls under the fallback category Regulatory Filings (RNS).
2026-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
Regulatory Filings Classification · 98% confidence The document is an HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” providing periodic compliance information on share capital, issued shares, treasury shares, and public float sufficiency. It is a routine listing rule return filed with the exchange rather than a full financial report, dividend notice, proxy statement, or specific capital-raising announcement. This falls under general regulatory/compliance filings (fallback category).
2026-06-03 English
FORM OF PROXY FOR USE AT THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 24, 2026
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form of Proxy for use at the company’s 2025 Annual General Meeting, providing instructions to shareholders on appointing proxies and voting on resolutions at the AGM. This is part of the proxy solicitation materials sent to shareholders. Therefore, it should be classified as a Proxy Solicitation & Information Statement (PSI).
2026-06-01 English
NOTICE OF THE 2025 ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 87% confidence The document is a formal notice convening the 2025 Annual General Meeting of PegBio Co., Ltd., detailing date/time/location, resolutions to be voted on, proxy appointment procedures, and related meeting logistics. This is not the actual AGM presentation materials or results, nor is it a financial report or regulatory certification. It is issued to shareholders to provide information and solicit proxy votes for the upcoming meeting, fitting the definition of a Proxy Solicitation & Information Statement (PSI).
2026-06-01 English
2025 AGM Circular
Proxy Solicitation & Information Statement Classification · 98% confidence The document is a shareholder circular containing the notice of the Annual General Meeting, detailed resolutions to be proposed (reports of the Board and Supervisory Committee, annual audited financial statements, profit distribution plan, capital proposals, director appointments, auditor re-appointment, share mandates, etc.), and a proxy form. It is not the standalone annual report or financial statements filing, but rather a solicitation of shareholder votes and information in connection with the AGM. This matches a Proxy Solicitation & Information Statement.
2026-06-01 English
VOLUNTARY ANNOUNCEMENT CR059 ACCEPTED BY EASD 2026 AND SELECTED FOR THE ORAL DISCUSSION PRESENTATION SESSION
Regulatory Filings Classification · 92% confidence The document is a voluntary announcement filed on the Hong Kong Exchange about the acceptance of the company’s research (CR059) for presentation at an academic conference. It contains no financial statements, no shareholder votes, no management changes, no merger/acquisition or capital actions, nor does it certify or publish a formal report. This fits as a general regulatory announcement or miscellaneous filing. Therefore, it should be classified as Regulatory Filings (RNS).
2026-06-01 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.